RadioMedix是一家临床阶段的放射药物公司,宣布由Fusion Pharmaceuticals收购其225Ac-PSMA-I&T资产。Fusion Pharmaceuticals是一家临床阶段肿瘤学公司,专注于开发作为精准药物的下一代放射性药物。225Ac-PSMA-I&T目前正在进行一项医师赞助的新药(IND)II期研究(简称TATCIST试验)下进行评估。RadioMedix还将为Fusion提供制造...
与对照组相比,225Ac-rhPSMA-10.1治疗显著降低了体内肿瘤生长(从第14天至31天,p<0.05),延长了生存期 (中位生存期:未治疗组、225Ac-rhPSMA-10.1组和177Lu-rhPSMA-10.1组分别为27、43.5和42天)。225Ac-rhPSMA-10.1组和177Lu-rhPSMA-10.1组在肿瘤生长抑制或生存期方面无显著差异,两种治疗均显示...
European Journal of Nuclear Medicine and Molecular Imaging -doi:10.1007/S00259-020-05023-2Harun IlhanAstrid GosewischGuido BningFriederike VlterMathias ZacherlMarcus UnterrainerPeter BartensteinAndrei TodicaFranz Josef GildehausSpringer Science and Business Media LLCEuropean Journal of Nuclear Medicine and ...
临床进展最快的是BMS和Rayzebio公司的225Ac-DOTATATE(临床3期)、阿斯利康和Fusion Pharmaceuticals的225Ac-PSMA I&T(临床2\3期) ,Cornell University与默沙东公司的225Ac-J591(PSMA)(临床1\2期)、Cornell University与默沙东公司的225Ac-J591(PSMA)(临床1\2...
Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-emitting 177Lutetium has already been investigated in several early phase dosimetry studies, demonstrated promising results in phase-2, and recently the first phase-3 trial finished recruitment. In contrast, PSMA-targeting...
Ac-225-PSMA617: a single center experience of 40 patients receiving PSMA-targeted alpha therapy. Soc Nucl Med 2016 doi:10.2967/jnumed.116.178673 14. Lindmo T, Boven E, Mitchell JB, Morstyn G, Bumm PA (1985) Specific kill...
Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer Eur. Urol. (2018) T. Hernandez-Jimenez et al. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: synthesis and assessment of the ability to target the prostate ...
Development of an Albumin-Based PSMA Probe with Prolonged Half-Life. Front. Mol. Biosci. 2020, 7, 585024. [CrossRef] 23. Beyer, G.J.; Bergmann, R.; Schomäcker, K.; Rösch, F.; Schäfer, G.; Kulikov, E.V.; Novgorodov, A.F. Comparison of the Biodistribution of 225Ac and...
Correction to: <Superscript>225</Superscript>Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study 来自 Springer 喜欢 0 阅读量: 8 作者: M Sathekge,F Bruchertseifer,O Knoesen,F Reyneke,I Lawal,T Lengana,C Davis,J Mahapane,C Corbett,M Vorster 展开...
Bruchertseifer, O. Knoesen, F. Reyneke, I. Lawal, T. Lengana, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study Eur. J. Nucl. Med. Mol. Imaging, 46 (1) (2019), pp. 129-138 CrossrefView in ScopusGoogle Scholar Sweat et al., ...